Supplementary Table S1 from Receptor-interacting Protein Kinase 2 Is an Immunotherapy Target in Pancreatic Cancer

Supplementary Table S1. MAGeCK analysis of CRISPR screen results to identify regulator of immune evasion in orthotopic PDAC mouse models.</p

Supplementary Table S3 from Receptor-interacting Protein Kinase 2 Is an Immunotherapy Target in Pancreatic Cancer

Supplementary Table S3. Detailed information of reagents and resources used in this study.</p

Supplementary Table S2 from Receptor-interacting Protein Kinase 2 Is an Immunotherapy Target in Pancreatic Cancer

Supplementary Table S2. Detailed information of human pancreatic tissue array.</p

SUPPLEMENTARY DATA FIGURES from Receptor-interacting Protein Kinase 2 Is an Immunotherapy Target in Pancreatic Cancer

Supplementary Figure S1. In vivo CRISPR screens to identify critical drivers of immune evasion; Supplementary Figure S2. Effects of Ripk2 depletion on tumor growth; Supplementary Figure S3. RIPK2 is overexpressed in human and mouse PDAC tissues; Supplementary Figure S4. Ablation of RIPK2 disrupts the desmoplastic TME; Supplementary Figure S5. RIPK2 modulates the immune profile and impairs anti-tumor T cell response; Supplementary Figure S6. RIPK2 restricts the activation and effector states of CD8+ T cells by impairing antigen presentation; Supplementary Figure S7. RIPK2 promotes MHC-I trafficking to lysosomes via NBR1; Supplementary Figure S8. RIPK2 ubiquitination promotes NBR1-mediated MHC-I degradation; Supplementary Figure S9. RIPK2 ablation potentiates the efficacy of PD-1 blockade; Supplementary Figure S10. Diagram illustrating RIPK2-mediated degradation of MHC I through autophagy–lysosome system.</p

Supplementary Table S4 from Receptor-interacting Protein Kinase 2 Is an Immunotherapy Target in Pancreatic Cancer

Supplementary Table S4. Primers used for qPCR or generating knockout/knockdown constructs.</p

Supplementary Table S3 from Receptor-interacting Protein Kinase 2 Is an Immunotherapy Target in Pancreatic Cancer

Supplementary Table S3. Detailed information of reagents and resources used in this study.</p

Supplementary Table S4 from Receptor-interacting Protein Kinase 2 Is an Immunotherapy Target in Pancreatic Cancer

Supplementary Table S4. Primers used for qPCR or generating knockout/knockdown constructs.</p

Supplementary Table S2 from Receptor-interacting Protein Kinase 2 Is an Immunotherapy Target in Pancreatic Cancer

Supplementary Table S2. Detailed information of human pancreatic tissue array.</p

SUPPLEMENTARY DATA FIGURES from Receptor-interacting Protein Kinase 2 Is an Immunotherapy Target in Pancreatic Cancer

Supplementary Figure S1. In vivo CRISPR screens to identify critical drivers of immune evasion; Supplementary Figure S2. Effects of Ripk2 depletion on tumor growth; Supplementary Figure S3. RIPK2 is overexpressed in human and mouse PDAC tissues; Supplementary Figure S4. Ablation of RIPK2 disrupts the desmoplastic TME; Supplementary Figure S5. RIPK2 modulates the immune profile and impairs anti-tumor T cell response; Supplementary Figure S6. RIPK2 restricts the activation and effector states of CD8+ T cells by impairing antigen presentation; Supplementary Figure S7. RIPK2 promotes MHC-I trafficking to lysosomes via NBR1; Supplementary Figure S8. RIPK2 ubiquitination promotes NBR1-mediated MHC-I degradation; Supplementary Figure S9. RIPK2 ablation potentiates the efficacy of PD-1 blockade; Supplementary Figure S10. Diagram illustrating RIPK2-mediated degradation of MHC I through autophagy–lysosome system.</p

Supplementary Table S1 from Receptor-interacting Protein Kinase 2 Is an Immunotherapy Target in Pancreatic Cancer

Supplementary Table S1. MAGeCK analysis of CRISPR screen results to identify regulator of immune evasion in orthotopic PDAC mouse models.</p